课题基金 / 基金详情

A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer

A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer
一种新的组蛋白 H3 修饰调节乳腺癌的表观遗传编程和基因表达
批准号:
10607954
负责人:
Qing Zhang
金额:
$44.37万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-12-08 至 2027-11-30

项目摘要

项目成果

Qing Zhang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Distinct histone modifications, on N or C-terminal tails, act as a “histone code” to elicit downstream events. Histone subunit post-translational modification (PTM), such as methylation, acetylation and phosphorylation regulates epigenetic regulation and gene expression in diseases such as cancer. Here we identified a new PTM on H3 called hydroxylation on proline 16, which is catalyzed by proline hydroxylase EglN2. Our preliminary data show that EglN2-mediated H3 Pro16-OH leads to increased Lysine (K)-Specific Demethylase 5A (KDM5A) binding corresponding with decreased H3K4me3 in breast cancer. We hypothesize that H3 prolyl hydroxylation mediated by EglN2 recruits KDM5A therefore controlling gene expression important in breast cancer. This is the first study reporting H3 Prolyl hydroxylation and its potential role in epigenetic regulation and gene expression in cancer. In Specific Aim 1, we will determine the effet of H3 prolyl hydroxylation on epigenetic regulation and gene expression on a genome wide scale in breast cancer cells. In Specific Aim 2, we will elucidate the molecular mechanism by which H3 prolyl hydroxylation regulates epigenetic reprogramming by recruiting KDM5A. In Specific Aim 3, we will elucidate the molecular mechanism by which H3 prolyl hydroxylation regulates Wnt/b-Catenin signaling in breast cancer cells. Successful completion of this proposal will characterize a new H3 post-translational modification in its epigenetic regulation and gene expression important in breast cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification of DCLK2-TBK1 signaling axis as a potential therapeutic target in kidney cancer
  • 批准号:
    10752584
  • 项目类别:
  • 资助金额:
    $48.57万
  • 财政年份:
    2023
  • 负责人:
    Qing Zhang
  • 依托单位:
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer
  • 批准号:
    10393664
  • 项目类别:
  • 资助金额:
    $39.39万
  • 财政年份:
    2021
  • 负责人:
    Qing Zhang
  • 依托单位:
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer
  • 批准号:
    10231769
  • 项目类别:
  • 资助金额:
    $40.38万
  • 财政年份:
    2021
  • 负责人:
    Qing Zhang
  • 依托单位:
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer
  • 批准号:
    10577757
  • 项目类别:
  • 资助金额:
    $38.72万
  • 财政年份:
    2021
  • 负责人:
    Qing Zhang
  • 依托单位:
海外基金